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Susceptibility to addiction has a complex genetic basis that includes genes associated with the action and metabolism of 
drugs of abuse. One important gene in that respect is OPRM1, which codes for the μ-opioid receptor and has an important 
role in mediating the rewarding effects of addiction substances. The aim of our study was to assess the prevalence of the 
OPRM1 A118G polymorphism (rs1799971) in Turkish population and to investigate its association with opioid and other 
substance addiction. In addition, we examined the association of rs1799971 in addicted patients who were also diagnosed 
with psychiatric disorders. The study included 103 patients addicted to opioids, cocaine, ecstasy, alcohol, lysergic acid 
diethylamide (LSD), cannabis, and sedative/hypnotic substances and 83 healthy volunteers with similar demographic 
features as controls. rs1799971 polymorphisms were identified with the polymerase chain reaction restriction fragment 
length polymorphism method (PCR-RFLP). The genotype frequencies were significantly higher in the addicted patients 
than controls (32.0 % vs 16.9 %, respectively; p=0.027). The prevalence of the G allele was 16.1 % in the addicted group 
and 8.4 % in the control group (p=0.031). Our study confirmed the association between the rs1799971(G) allele frequency 
and opioid and other substance addiction, but not with psychiatric disorders.
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Addiction is a chronic, relapsing, complex, and 
polygenic brain disease. Genetic factors in its aetiology are 
associated with pathophysiological mechanisms of reward 
pathways, which include ventral tegmental area (VTA), 
nucleus accumbens, and the prefrontal cortex (1). There are 
several neurotransmitters and receptors on reward 
pathways, the most important of which are dopamine, 
opioids, serotonin, gamma-aminobutyric acid (GABA), and 
their receptors. One of these receptors is the μ-opioid 
receptor, whose signal is activated by several opioid or 
non-opioid drugs of abuse (2), and is a potential target for 
addiction therapy. It is also widely studied for addiction 
susceptibility in different populations.
The μ-opioid receptor is encoded by the OPRM1 gene, 
which is 90 kb long and located on chromosome 6q24–q25 
(3). Inter-individual differences in the μ-opioid receptor 
function may be partly attributed to genetic variations in 
OPRM1 (4). This gene contains 273 single-nucleotide 
polymorphisms (SNPs), of which the nonsynonymous 
variant rs1799971 (A118G, Asn40Asp, exon 1), which 
removes the N-glycosylation site in the OPRM1 extracellular 
domain, attracts most research attention (5).
Reports on the role of the OPRM1 A118G gene 
polymorphism in substance addiction are conflicting (6–10). 
Moreover, some ethnic groups have not yet been studied 
for this µ-opioid receptor polymorphism, and one of them 
is the Turkish population.
Several studies also investigated the association 
between the OPRM1 A118G polymorphism and psychiatric 
disorders in psychiatric patients, but the reports were also 
controversial and suggested further research to explain the 
confounding influence of population characteristics and 
geographic location (11–13).
To address these gaps in knowledge for the Turkish 
population, the primary aim of our study was to assess the 
distribution of the OPRM1 A118G gene polymorphism 
among Turkish addicts and healthy volunteers to see 
whether this polymorphism is associated with substance 
addiction. Our secondary aim was to establish the frequency 
of this genetic polymorphism in addictive patients who were 
also diagnosed with psychiatric disorders to see if it is also 
associated with psychiatric disorders among addicts.
Corresponding author: Hülya Türkan, MD, PhD, Bozok University, 
Department of Anaesthesiology and Reanimation, 661200, Yozgat, Turkey, 
E-mail: hulyaturkan@hotmail.com
Türkan H, et al. The association between the OPRM1 A118G polymorphism and addiction in a Turkish population 
Arh Hig Rada Toksikol 2019;70:97-103
98
PARTICIPANTS AND METHODS
Study participants and sample collection
Our case-control study consisted of 103 substance-
addicted patients [mean age: 29.62±7.62 (range=30–62) 
years; 87 men and 16 women] and 83 healthy, non-smoking, 
and non-addicted volunteers who served as control [mean 
age: 31.99±6.83 (range=21–49) years; 58 men and 25 
women].
The addicted patients had been using opioid, cocaine, 
ecstasy, alcohol, LSD, cannabis, and sedative/hypnotic 
substances and were hospitalised at the Alcohol and 
Substance Research, Treatment and Training Center 
(AMATEM) of the Bakirkoy Training and Research 
Hospital in İstanbul between 2008 and 2009. Addicted 
patients were examined and assessed by a psychiatrist 
specialised in substance abuse and all met the criteria for 
opiate dependence, as defined by Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) 
(14). They completed a detailed personal, medical, and 
specific addictive disease questionnaire, which also 
included behavioural assessment, substance-taking history 
and information about the diagnosed psychiatric disease, 
such as depression or psychosis. Controls had no personal 
or family history of alcohol or other substance addiction. 
The study was approved by the Ethics Committee of 
AMATEM, and all participants gave their informed consent 
in writing before enrolment.  After the informed consent, 
10 mL of peripheral blood were taken from each participant 
via venipuncture and stored in a sterile EDTA for genetic 
analysis.
DNA isolation and analysis of OPRM1 A118G 
polymorphism
DNA was extracted from whole blood using a sodium 
perchlorate/chloroform extraction method (15). After the 
extraction, polymerase chain reaction restriction fragment 
length polymorphism (PCR-RFLP) method was used for 
the amplification of DNA fragment with the A118G 
polymorphism in the promoter region of the OPRM1 gene 
and its analysis on agarose gel. The forward primer used 
for PCR was 5’-GGTCAACTTGTCCCACTTAGATGGC-3’ 
and the reverse primer was 5’-AAACTTCCTGGTG 
ATGTATGTGATT-3’ (Thermo Fischer Scientific, Ulm, 
Germany). The PCR reaction was carried out in total 
volumes of 15 µL containing 200 ng of DNA, 1.5 mmol/L 
of MgCl2, 0.25 µmol of each primer, 0.1 mmol/L of each 
dNTP (dATP, dCTP, dGTP, dTTP), 1 U of Taq DNA 
polymerase (Fermentas Life Sciences, Vilnius, Lithuania). 
PCR conditions consisted of an initial denaturing step at 
94 °C for 3 min, followed by 38 cycles of a 30 s denaturing 
step at 94 °C, a 1 min annealing step at 62 °C, and a 1 min 
extension step at 72 °C. At the end of the reaction, there 
was a final extension step at 72 °C for 10 min. Eight 
microliters of PCR products were loaded on 2 % agarose 
gels (1×TBE buffer, for 10 min at 120 V) to confirm the 
amplification. The 193 bp long amplified fragments were 
then digested overnight with the BstU1 at 60 °C, using 
10 µL of the PCR product, 1 U of the BstU1 restriction 
endonuclease (Fermentas Life Sciences), and 2 μL of 
buffers. The digested fragments were separated by 
electrophoresis in 10 % polyacrylamide gels (PAGE) in 
1×TBE buffer at 160 V for 3 h. The length of the resulting 
genotype fragments was 193 bp (A118A); 193 bp, and 169 
bp (A118G); and 169 bp (G118G) (Figure 1).
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Figure 1 Agarose gel picture illustrating OPRM1 A118G genotypes identified by PCR-RFLP using the Bst UI restriction enzyme. 
Column 1 is a 100 bp marker, columns 2, 3, 4, 6, and 7 are samples of persons carrying the wild type A118A genotype, and column 5 
a sample of a person carrying the heterozygous A118G genotype
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Statistics
Data were analysed using the statistical package SPSS 
version 11.5 (SPSS Inc., Chicago, IL, USA) and the results 
expressed as means ± SD. Allele frequencies were 
calculated from counted genotype frequencies. Hardy-
Weinberg equilibrium was tested. Differences in genotype 
distribution and allele frequencies between the addicted and 
control groups were tested with the chi-square test. To 
evaluate the association between the higher risk of addiction 
and the A118G polymorphism, odds ratios (ORs) with 95 % 
confidence intervals (CIs) were determined for each variable 
with multiple logistic regression models. A p value of less 
than 0.05 was considered statistically significant.
For the statistical power calculation we used G*Power 
version 3 (Heinrich Heine University of Düsseldorf, 
Düsseldorf, Germany). Since our sample consisted of 
addicted and control subjects, its power, when probability 
of exposure among controls was 0.169 and among cases 
was 0.32, turned out to be 0.659.
RESULTS
Besides demographic information, we also investigated 
the substance taking history of patients. Unfortunately, some 
of the patients decided not to answer all of the questions in 
the questionnaire and therefore group sizes (N) differ 
between variables in the tables. Table 1 summarises some 
of the demographic and addiction data of the patients group.
Genotype and allele frequencies of the OPRM1 A118G 
polymorphism in addicted patients and controls are given 
in Table 2. The variant allele (G118) frequencies were 
significantly different between patients (16.1 %) and 
controls (8.4 %) [(p=0.031; OR=2.07 (1.68–4.01)] as well 
as the frequencies of the A118G genotype [(p=0.027; 
OR=2.32 (1.14–4.72)]. The OR of 2.32 means that the risk 
of addiction is more than two times higher in patients 
carrying the heterozygote genotypes than patients carrying 
the wild genotype. No deviation from Hardy-Weinberg 
equilibrium was observed for any of the genotypes studied.
Table 3 shows that the frequency of the OPRM1 A118G 
genotypes did not significantly differ by the substance of 
abuse, which suggests that there was no association between 
the OPRM1 A118G gene polymorphism and the predilection 
for a particular substance.
Table 4 shows that the frequency of the OPRM1 A118G 
genotypes did not significantly differ between addictive 
patients with and without psychiatric disorders and was 
therefore not associated with psychiatric disorders.
DISCUSSION
Some SNPs in particular genes may affect the tendency 
towards alcoholism and opiate addiction, its treatment, and 
relapse (4–5). The OPRM1gene has more than 800 SNPs, 
and the OPRM1 A118G gene polymorphism (rs1799971) 
is its widely studied variation (16–20).
The frequency of the A118G variant allele of 0.084 in 
healthy Turkish population established by this study places 
it with the European Caucasian populations, namely 
Swedish (6), Norwegian (23), and Hispanic (24) (Table 5) 
in between the African American population at the lowest 
end of the range and Asian populations at the higher end 
(21–33).
As for the secondary aim, this is the first study to 
investigate and confirm the association between the OPRM1 
A118G polymorphism and increased risk of addiction in a 
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Table 1 Demographic and addiction characteristics of addicted patients. The number of respondents in the rows varies because not all 
the participants answered all the questions
Variable A118A A118G
Age (years), N=97 29.24±6.98 (23–45) 30.46±8.93 (20–28)
Age at beginning of addiction (years), N=97 18.38±4.47 (19–25) 17.58±7.08 (12–22)
Gender (M/F), N=103 57/12 31/3
N (%) N (%)
Family history of addiction (addicted/total), N=90 4/61 (6.56) 5/29 (17.2)
Smoking history before addiction (smoking history/total), N=94 8/64(12.5) 6/30 (20.0)
Education, N=95
Primary 32 (50) 12 (38.7)
High School 18 (28.1) 7 (22.5)
University 8 (12.5) 5 (16.1)
Doctorate 6 (9.3) 7 (22.5)
Reason for starting drug abuse, N=72
Curiosity 12 (24.4) 1 (0.04)
Friend’s advice 35 (71.4) 16 (0.69)
Family problems 1 (0.02) 5 (0.21)
Economic problems 1 (0.02) 1 (0.04)
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Turkish population. Similar association was reported in 
European populations by Bart et al. (6) and Bergen et al. 
(9) and in Asian populations by Luo et al. (10), Loh et al. 
(8), and Kim et al. (29). By contrast, Arias et al. (34) reported 
no such association based on their meta-analysis of 
combined data from multiple studies about opioids, alcohol, 
nicotine, and cocaine addiction. Chen et al. (35), however, 
conducted an ethnicity-specific meta-analysis limited to 
alcohol addiction and found that the G118 variant of the 
OPRM1 A118G polymorphism contributed to the 
susceptibility of alcohol addiction in Asians but not in 
Caucasians.
Some researchers studied each addictive substance 
separately (3, 6, 7, 36), while others studied combined 
opioids, alcohol, and cocaine (10, 24, 37). In our study, we 
enrolled all abusers of all substances. What we did 
differently from similar studies (24, 37) is that we evaluated 
substance addiction and polymorphism association both for 
all substances together and by each substance taken as a 
separate variable. The first analysis showed a significant 
association between substance addiction and the OPRM1 
A118G gene polymorphism, but the second did not. This 
might be due to our small sample size.
While most of the studies of the association between 
the OPRM1 polymorphism and addiction do not specify 
whether major mental illness was an exclusion criterion 
(7–9, 27), Bond et al. (3) and Ide et al. (31) did exclude 
addicts with anxiety and psychotic disorders. We included 
addicted patients with major mental illness in our study to 
assess the frequency of the A118G polymorphism in these 
patients as well, but found out that the G allele frequency 
was not significantly associated with mental disorders in 
the addiction group. Our results suggest that the A118G 
polymorphism does not increase the risk of addiction by 
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Table 2 Genotype and allele frequencies of the OPRM1 A118G polymorphism in the addicted patients and controls
Variable Controls N (%)
Patients 
N (%) OR (95 %CI) P*
A118A genotype 69 (83.1) 70 (68.0) 1.0
0.027A118G genotype 14 (16.9) 33(32) 2.32 (1.144–4.718)
G118G genotype 0 (0) 0 (0) -
A118 allele 152 (91.8) 173 (83.9) 1.0
0.031
G118 allele 14 (8.4) 33 (16.1) 2.07 (1.68–4.01)
* logistic regression; Wild-type allele = A, mutated allele = G, heterozygous genotype = A/G, homozygous genotype = A/A, G/G; OR 
– odds ratio; CI – 95 % confidence interval
Table 3 Frequency of the OPRM1 A118G genotypes by substance of addiction
Substance used by addicted patients A118A genotype
A118G 
genotype OR (95 % CI) P*
Opioid (user/total, % of users), N=96 23/65 (35.4) 14/31(54.8) χ2=3,268; 2.217 (0.278–1.589) 0.081
Cocaine (user/total, % of users), N=96 23/65 (35.4) 8/31(25.8) χ2=0,881; 0.635 (0.607–4.079) 0.484
Ecstasy (user/total, % of users), N=96 22/65 (33.8) 10/31(32.3) χ2=0,024; 0.909 (0.431–2.674) 0.877
LSD (user/total, % of users), N=96 6/65 (9.2) 6/31(19.4) χ2=1,967; 2.36 (0.124–1.442) 0.193
Alcohol (user/total, % of users), N=96 25/65 (38.5) 12/31(38.7) χ2=0.001; 1.011 (0.410–2.383) 1
Sedative/hypnotic (user/total, % of users), N=85 0/58 (0) 1/27(3.7) χ2=2,174; 6.623 (0.005–3.833) 0.318
Cannabis (user/total, % of users, N=81 36/62 (58.1) 17/29 (58.6) χ2=0,003; 1.023 (0.399–2.392) 1
* logistic regression; OR – odds ratio; CI, 95 % confidence interval





N (%) OR (95 % CI) P*
Psychiatric disorder/therapy history 20 (32.3) 13 (43.3)
χ2=1,078;1.606 (0.654–3.940) 0.356
No psychiatric disorder/therapy history 42 (67.7) 17 (56.7)
Total 62(100) 30(100)
* logistic regression; OR – odds ratio; CI, 95 % confidence interval
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causing psychiatric disorders, but since they are the first to 
contradict the findings of Trosi et al. (11) and Serý et al. 
(13), more research is needed to make this issue clear.
Of course, there are some important limitations to 
interpreting our study results. First, the sample size was too 
small to provide sufficient power and allow definitive 
conclusions. Second, we did not include other SNPs because 
of technical reasons. These issues should be addressed by 
large population trials that will include other SNPs.
In conclusion, we would like to point out that this is the 
first study of the kind conducted in a Turkish population. 
Despite its limitations, we believe that our findings 
contribute to the database of the OPRM1 A118G 
polymorphism frequency and its association with substance 
addiction. Future research should combine several 
polymorphisms to determine their association with each 
substance of abuse not only in Turkey but also worldwide 
to figure out which gene interactions could lead to 
improvements in pharmacogenetic treatment. Future 
research of the molecular mechanisms of opiate dependence 
and tolerance in humans should also focus on genetic-
epigenetic interactions, including methylation, which seems 
to significantly contribute to how genetic polymorphisms 
affect propensity for addiction.
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Povezanost genskoga polimorfizma OPRM1 A118G s ovisnosti u turskoj populaciji
Sklonost ovisnosti ima svoju složenu gensku pozadinu, koja obuhvaća gene povezane s djelovanjem i metabolizmom 
opojnih tvari i droga. U tom je smislu jedan od istaknutih gena OPRM1, koji kodira µ-opioidni receptor te ima važnu 
ulogu u nagradnom djelovanju tvari koje stvaraju ovisnost. Cilj je ovoga istraživanja bio utvrditi prevalenciju OPRM1 
A118G polimorfizma (rs1799971) u turskoj populaciji te njegovu povezanost s ovisnosti o opijatima i drugim drogama. 
Usto smo istražili povezanost rs1799971 u ovisnika s dijagnozom psihijatrijskih poremećaja. Istraživanje je obuhvatilo 
103 ovisnika o opioidima, kokainu, ekstaziju, alkoholu, lizergidu (LSD-u), kanabisu i o sedativima/hipnoticima, odnosno 
83 zdrava dobrovoljca sličnih demografskih karakteristika koji su poslužili kao kontrolna skupina. Polimorfizmi rs1799971 
utvrđeni su pomoću metode lančane reakcije polimerazom s obzirom na dužinu restrikcijskoga fragmenta (PCR-RFLP). 
Učestalost ciljanoga genotipa bila je značajno viša u ovisnika nego u kontrolnih ispitanika (32,0 % odnosno 16,9 %; 
p=0,027), a učestalost G alela iznosila je 16,1 % u ovisnika, odnosno 8,4 % u kontrolnoj skupini (p=0,031). Time je naše 
istraživanje potvrdilo povezanost između učestalosti rs1799971(G) alela i ovisnosti o opioidima i drugim opojnim tvarima, 
ali ne i povezanost s psihijatrijskim poremećajima.
KLJUČNE RIJEČI: alkohol; ecstasy; hipnotici; kanabis; kokain; LSD; opioidi; psihijatrijski poremećaji; rs1799971; 
sedativi; μ-opioidni receptor
